Holdings
Vestal Point Capital, LP
As of Jun 30, 2026, Vestal Point Capital, LP reported 60 positions worth US$3.89B. Largest: Biomarin Pharmaceutical Inc., Neurocrine Biosciences, Inc. and Abivax Sa. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc. | 6.03M | US$345M | +2.45M | Jun 30, 2026 |
| Neurocrine Biosciences, Inc. | 1.88M | US$317M | +630K | Jun 30, 2026 |
| Abivax Sa | 2.35M | US$313M | +849K | Jun 30, 2026 |
| United Therapeutics Corporation | 435K | US$236M | +360K | Jun 30, 2026 |
| Enliven Therapeutics, Inc. | 4M | US$203M | +750K | Jun 30, 2026 |
| Nurix Therapeutics, Inc. | 8.05M | US$195M | +1.55M | Jun 30, 2026 |
| Bicara Therapeutics Inc. | 5.25M | US$156M | −175K | Jun 30, 2026 |
| Taysha Gene Therapies, Inc. | 19.4M | US$132M | +1.42M | Jun 30, 2026 |
| Arrowhead Pharmaceuticals, Inc. | 1.57M | US$128M | −700K | Jun 30, 2026 |
| Abbott Laboratories | 1.4M | US$127M | new | Jun 30, 2026 |